Ionis Announces FDA Review of Donidalorsen NDA for Preventive Treatment of HAE
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted therapy for preventing hereditary…
WHO Study Identifies Key Endemic Pathogens in Urgent Need of New Vaccines
A recent World Health Organization (WHO) study, published in eBioMedicine, has identified 17 priority pathogens that are endemic in various communities and urgently require new vaccines. This marks WHO’s first…
Libra Therapeutics Names Dr. Shawn A. Scranton as President and CEO
Libra Therapeutics, Inc., a private biotechnology company focused on developing innovative therapies to restore cellular balance and reduce neurodegeneration, has announced the appointment of Shawn A. Scranton, PharmD, as President…
Kashiv BioSciences Names Dr. Sandeep Nilkanth Athalye as Global CEO
Kashiv BioSciences, LLC, a globally integrated biopharmaceutical company, has appointed Dr. Sandeep Nilkanth Athalye as its new Global Chief Executive Officer. With over 20 years of experience in strategic and…
Medidata and Cogstate Partner to Enhance Neurology Clinical Trials with AI Solutions
Medidata, a brand of Dassault Systèmes and a leading provider of clinical trial solutions, has partnered with Cogstate, a leader in neuroscience solutions, to transform clinical trials and outcome measurements…
Vir Biotechnology Releases Q3 2024 Financial Results and Corporate Update
Vir Biotechnology, Inc. (Nasdaq: VIR) has released its corporate update and financial results for the third quarter ended September 30, 2024. “This quarter marked a transformative period for Vir. We…
Lilly to Present Phase 3 EMBER-3 Study Results for Imlunestrant at San Antonio Breast Cancer Symposium
Eli Lilly and Company (NYSE: LLY) has announced that data from the Phase 3 EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader (SERD), will be presented for the…
Ma Xin, Jiangsu Vice Governor, Visits Hansoh Pharma Subsidiary
On the morning of October 30, Ma Xin, a member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, visited Jiangsu Hansoh, a subsidiary of…
ASN 2024 | Hansoh Pharma Shares Post-Hoc Results from Phase III Pegmolesatide Study
The 2024 American Society of Nephrology (ASN) Kidney Week conference took place at the San Diego Convention Center from October 23 to 27. During this event, a post-hoc analysis of…
Teva Unveils New Schizophrenia Research: Positive Phase 3 TEV-‘749 and UZEDY® Data
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has announced encouraging new data from the Phase 3 SOLARIS trial on TEV-‘749, a subcutaneous extended-release…
Teva Presents New TD Data at Psych Congress 2024, Highlighting Patient Differences
Teva Pharmaceuticals, the U.S. branch of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has released interim findings from its Phase 4 IMPACT-TD Registry study. This large-scale study sheds light…
New WHO Report Highlights Urban Efforts in Preventing NCDs and Injuries
On World Cities Day, the World Health Organization (WHO) launched a new report highlighting how urban areas can tackle the increasing challenges posed by noncommunicable diseases (NCDs) and injuries. As…